Sequana announced that the Centers for Medicare and Medicaid Services (CMS) recommends that alfapump system cases be eligible for incremental payment via a new technology add-on payment (NTAP). This proposal could bring an NTAP top-up payment of up to $ 19,500 on top of the existing DRG payments, boosting the device's reimbursement position, and could make the alfapump procedure profitable for hospitals, which is likely to help drive adoption. With center training due to be completed by the end ...
Yesterday, Fagron hosted a Capital Markets Day where it laid out its strategic priorities for 2030. We see the updated Compounding for Growth strategy as a natural extension of the successful current trajectory. Financial targets are set for HSD-LDD organic CER revenue growth, a 21.0% REBITDA margin by 2027 progressively increasing thereafter to 2030, =70% operating cash conversion, =50% FCF conversion and 3.5% maintenance capex. Management continues to expect solid organic growth across all reg...
Fagron publishes agenda for 2025 annual shareholders meeting Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 11 April 2025 – 8 AM CET Fagron publishes agenda for 2025 annual shareholders meeting The Board of Directors of Fagron NV invites shareholders to attend Fagron’s annual general meeting of shareholders on Monday 12 May 2025. AgendaThe agenda includes the discussion of the annual report, the approval of the annual financial statements and the dividend proposal of €0.35 for the financial year 2024, and the approval of the remuneration policy. The full agenda and ...
Fagron publiceert agenda jaarlijkse aandeelhouders-vergadering 2025 Gereglementeerde informatieNazareth (België)/Rotterdam (Nederland), 11 april 2025 – 8u CET Fagron publiceert agenda jaarlijkse aandeelhouders-vergadering 2025 De Raad van Bestuur van Fagron NV nodigt de aandeelhouders uit om de jaarlijkse algemene vergadering van aandeelhouders van Fagron bij te wonen op maandag 12 mei 2025. AgendaOp de agenda staan onder andere de bespreking van het jaarverslag, de goedkeuring van de jaarrekening en het dividendvoorstel van €0,35 over het boekjaar 2024 en de goedkeuring van het remun...
1Q25 results outperformed our and CSS expectations on the back of sustained high growth in N-Am's activities and strong CER performance in LatAm. The company reiterates its FY25 guidance and provides realistic mid-term targets into 2030 at today's CMD. We reiterate € 24 TP/ Buy rating.
Fagron presenteert haar verbeterde groeistrategie en financiële doelstellingen op middellange termijn tijdens haar Capital Markets Day 2025 Gereguleerde informatieNazareth (België)/Rotterdam (Nederland), 10 april 2025 – 7.00 uur CET Fagron presenteert haar verbeterde groeistrategie en financiële doelstellingen op middellange termijn tijdens haar Capital Markets Day 2025 Fagron, de toonaangevende wereldwijde speler op het gebied van farmaceutische bereidingen, organiseert vandaag vanaf 14.00 uur CET haar Capital Markets Day 2025. Tijdens het evenement worden presentaties gegeven door CEO R...
Fagron to present its upgraded growth strategy and mid-term financial targets at its Capital Markets Day 2025 Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 10 April 2025 – 7AM CET Fagron to present its upgraded growth strategy and mid-term financial targets at its Capital Markets Day 2025 Fagron, the leading global player in pharmaceutical compounding will host its Capital Markets Day 2025 today from 2PM CET. The event will include presentations from CEO Rafael Padilla and CFO Karin de Jong, as well as regional and functional leaders. The Company will provide an upd...
Record first-quarter revenue of €239 million, reflecting 14% topline growth Regulated information - inside informationNazareth (Belgium)/Rotterdam (The Netherlands), 10 April 2025 – 7:00 AM CET Record first-quarter revenue of €239 million, reflecting 14% topline growth Fagron, the leading global player in pharmaceutical compounding, today publishes its quarterly results for the period ending 31 March 2025. Key Highlights Revenue maintained its strong growth momentum, increasing 14.1% on reported basis to €238.7 million (15.2% at CER), with all regions and segments contributingOrgani...
Recordomzet van € 239 miljoen in het eerste kwartaal, wat een omzetgroei van 14% weerspiegelt Gereglementeerde informatie - voorkennisNazareth (België)/Rotterdam (Nederland), 10 april 2025 – 07:00 uur CET Recordomzet van € 239 miljoen in het eerste kwartaal, wat een omzetgroei van 14% weerspiegelt Fagron, de toonaangevende wereldwijde speler in farmaceutische bereidingen, publiceert vandaag haar kwartaalresultaten voor de periode eindigend op 31 maart 2025. Belangrijkste hoogtepunten De omzet behield zijn sterke groeimomentum en steeg met 14,1% op gerapporteerde basis tot € 238,7 mi...
Trumps reciprocal tariffs caused a massive blow to equity markets, following a pressured period of escalating trade wars. Retaliatory measures can further heavily damage market confidence, as seen Friday when China announced their 34% tarrif of US goods. International trade policies have never moved this erratic and untransparant, with uncertainty and volatility being the baseline for now. In this report we highlight the key stocks in our coverage relevant to this discussion.
In this April 2025 update of the KBC Securities' Dynamic Top Pick List, we are removing Gimv and adding Adyen. Since adding Gimv to the Dynamic Top Pick List in mid-December 2024, Gimv's performance has remained flat. However, month-to-date, it has increased by nearly 7%, while the indices have all declined. Given the backdrop of a tariff war brewing, we think it's time to remove Gimv from the Dynamic Top Pick List as medium-sized businesses are more likely to feel the pinch of lower demand and...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.